Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Arrowhead Pharmaceuticals Closes Agreements with Janssen Worth Up To $3.7 Billion
Arrowhead Pharmaceuticals Closes Agreements with Janssen Worth Up To $3.7 Billion
Arrowhead Pharmaceuticals Closes Agreements with Janssen Worth Up To $3.7 Billion
Submitted by
admin
on October 31, 2018 - 11:03am
Source:
CP Wire
News Tags:
Arrowhead Pharmaceuticals
Janssen
JNJ
hepatitis B
Headline:
Arrowhead Pharmaceuticals Closes Agreements with Janssen Worth Up To $3.7 Billion
snippet:
Arrowhead will receive $175 million upfront
J&J will make a $75 million equity investment
Janssen receives a worldwide exclusive license to the ARO-HBV program
Do Not Allow Advertisers to Use My Personal information
